Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00

Context Therapeutics (NASDAQ:CNTX) had its target price raised by Piper Sandler from $4.00 to $7.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other analysts have also recently issued reports on the company. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Lifesci Capital raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. JonesTrading initiated coverage on shares of Context Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Context Therapeutics Price Performance

CNTX opened at $2.54 on Tuesday. The firm has a market capitalization of $233.38 million, a P/E ratio of -6.68 and a beta of 1.96. Context Therapeutics has a one year low of $0.49 and a one year high of $3.62. The company has a fifty day moving average price of $2.46 and a 200-day moving average price of $1.61.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). On average, analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Blue Owl Capital Holdings LP grew its position in Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after buying an additional 25,000 shares during the period. Vanguard Group Inc. raised its position in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the period. Millennium Management LLC purchased a new position in shares of Context Therapeutics during the 4th quarter worth $3,824,000. Marshall Wace LLP boosted its stake in shares of Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

More Context Therapeutics News

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target for CNTX to $7.00, giving investors a higher valuation anchor that could support upside if clinical or commercial progress validates the view. Piper Sandler Raises Context Therapeutics (NASDAQ:CNTX) Price Target to $7.00
• Positive Sentiment: Guggenheim initiated (or reiterated) a Buy on CNTX, a bullish signal that can attract momentum buyers and institutional interest. Context Therapeutics (NASDAQ:CNTX) Earns Buy Rating from Guggenheim
• Positive Sentiment: D. Boral Capital also gave CNTX a Buy rating, adding to the cluster of bullish broker opinions that may support demand at current levels. Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from D. Boral Capital
• Neutral Sentiment: HC Wainwright’s report includes a long‑range projection of a modestly positive FY2030 EPS ($0.08), implying the firm expects potential profitability by the end of the decade — a distant, high‑uncertainty view. MarketBeat: Context Therapeutics analyst note summary
• Negative Sentiment: HC Wainwright (analyst E. Bodnar) cut multiple near‑term EPS estimates on March 24th — trimming Q1–Q4 2026 and lowering FY2026–FY2029 forecasts (FY2026 revised to -$0.60 from -$0.49; FY2027–FY2029 also materially lowered). Those downgrades signal weaker expected near‑term economics and drove downward pressure on the stock today. MarketBeat: HC Wainwright cuts Context Therapeutics EPS estimates

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.